Mattias Mattsson

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

Al-Sawaf, Othman; Stumpf, Janina; Zhang, Can; Simon, Florian et al.

Part of New England Journal of Medicine, p. 1084-1096, 2026

• DOI for Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker

Thorvaldsdottir, Birna; Mansouri, Larry; Sutton, Lesley-Ann; Nadeu, Ferran et al.

Part of Leukemia, p. 1650-1660, 2025

• DOI for ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker
• Download full text (pdf) of ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial

Niemann, Carsten U.; Dubois, Julie; Nasserinejad, Kazem; da Cunha-Bang, Caspar et al.

Part of Blood Advances, p. 3665-3675, 2025

• DOI for Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial
• Download full text (pdf) of Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial

Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis

Ruefer, Axel; Nilius, Henning; Hermine, Olivier; Niedoszytko, Marek et al.

Part of Leukemia, p. 675-683, 2025

• DOI for Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis
• Download full text (pdf) of Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis

Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemia

Glimelius, Ingrid; Kleinstern, Geffen; Robinson, Dennis P.; Mansouri, Larry et al.

Part of eJHaem, p. 998-1004, 2024

• DOI for Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemia
• Download full text (pdf) of Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemia

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

Al-Sawaf, Othman; Stumpf, Janina; Zhang, Can; Simon, Florian et al.

Part of New England Journal of Medicine, p. 1084-1096, 2026

• DOI for Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker

Thorvaldsdottir, Birna; Mansouri, Larry; Sutton, Lesley-Ann; Nadeu, Ferran et al.

Part of Leukemia, p. 1650-1660, 2025

• DOI for ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker
• Download full text (pdf) of ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial

Niemann, Carsten U.; Dubois, Julie; Nasserinejad, Kazem; da Cunha-Bang, Caspar et al.

Part of Blood Advances, p. 3665-3675, 2025

• DOI for Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial
• Download full text (pdf) of Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial

Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis

Ruefer, Axel; Nilius, Henning; Hermine, Olivier; Niedoszytko, Marek et al.

Part of Leukemia, p. 675-683, 2025

• DOI for Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis
• Download full text (pdf) of Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis

Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemia

Glimelius, Ingrid; Kleinstern, Geffen; Robinson, Dennis P.; Mansouri, Larry et al.

Part of eJHaem, p. 998-1004, 2024

• DOI for Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemia
• Download full text (pdf) of Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemia

Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry

Niedoszytko, Marek; Gorska, Aleksandra; Brockow, Knut; Bonadonna, Patrizia et al.

Part of Allergy. European Journal of Allergy and Clinical Immunology, p. 2470-2481, 2024

• DOI for Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry

Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis

Iribarren, Cristina; Levedahl, Kerstin; Atanasoai, Ionut; Mattsson, Mattias et al.

Part of Journal of Molecular Diagnostics, p. 792-804, 2024

• DOI for Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis
• Download full text (pdf) of Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis

Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM

Lübke, Johannes; Schmid, Alicia; Christen, Deborah; Elberink, Hanneke N. G. Oude et al.

Part of Blood Advances, p. 2890-2900, 2024

• DOI for Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM
• Download full text (pdf) of Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM

Avapritinib versus Placebo in Indolent Systemic Mastocytosis

Gotlib, Jason; Castells, Mariana; Elberink, Hanneke Oude; Siebenhaar, Frank et al.

Part of NEJM EVIDENCE, 2023

• DOI for Avapritinib versus Placebo in Indolent Systemic Mastocytosis

Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry

Kennedy, Vanessa E.; Perkins, Cecelia; Reiter, Andreas; Jawhar, Mohamad et al.

Part of Blood Advances, p. 1713-1724, 2023

• DOI for Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

Mansouri, Larry; Thorvaldsdottir, Birna; Sutton, Lesley-Ann; Karakatsoulis, Georgios et al.

Part of Leukemia, p. 339-347, 2023

• DOI for Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY
• Download full text (pdf) of Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis

Lübke, Johannes; Schwaab, Juliana; Christen, Deborah; Elberink, Hanneke Oude et al.

Part of Journal of Allergy and Clinical Immunology, p. 581-590, 2023

• DOI for Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis

Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature

Del Giudice, Ilaria; Cappelli, Luca Vincenzo; Delgado, Julio; Niemann, Carsten Utoft et al.

Part of British Journal of Haematology, p. 353-356, 2023

• DOI for Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

Kater, Arnon P.; Levin, Mark-David; Dubois, Julie; Kersting, Sabina et al.

Part of The Lancet Oncology, p. 818-828, 2022

Cardiovascular disease in patients with chronic lymphocytic leukemia: A Swedish nationwide register study with matched comparators

Larsson, Karin; Soderling, Jonas; Höglund, Martin; Glimelius, Ingrid et al.

Part of American Journal of Hematology, 2022

• DOI for Cardiovascular disease in patients with chronic lymphocytic leukemia: A Swedish nationwide register study with matched comparators

Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?

Brieghel, Christian; Galle, Veerle; Agius, Rudi; Da Cunha-Bang, Caspar et al.

Part of European Journal of Haematology, p. 369-378, 2022

• DOI for Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?
• Download full text (pdf) of Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?

Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis

Zanotti, Roberta; Bonifacio, Massimiliano; Lucchini, Giuseppe; Sperr, Wolfgang R. et al.

Part of Leukemia, p. 516-524, 2022

• DOI for Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis

Five Percent Variant Allele Frequency Is a Reliable Reporting Threshold for TP53 Variants Detected by Next Generation Sequencing in Chronic Lymphocytic Leukemia in the Clinical Setting

Pandzic, Tatjana; Ladenvall, Claes; Engvall, Marie; Mattsson, Mattias et al.

Part of HemaSphere, 2022

• DOI for Five Percent Variant Allele Frequency Is a Reliable Reporting Threshold for TP53 Variants Detected by Next Generation Sequencing in Chronic Lymphocytic Leukemia in the Clinical Setting
• Download full text (pdf) of Five Percent Variant Allele Frequency Is a Reliable Reporting Threshold for TP53 Variants Detected by Next Generation Sequencing in Chronic Lymphocytic Leukemia in the Clinical Setting

Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis

Kluin-Nelemans, Hanneke C.; Jawhar, Mohamad; Reiter, Andreas; van Anrooij, Bjorn et al.

Part of Theranostics, p. 292-303, 2021

• DOI for Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis
• Download full text (pdf) of Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis

Assessing Patients' Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece

Karamanidou, Christina; Xochelli, Aliki; Papaioannou, Maria; Moysiadis, Theodoros et al.

Part of HemaSphere, 2021

• DOI for Assessing Patients' Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Chatzikonstantinou, Thomas; Kapetanakis, Anargyros; Scarfò, Lydia; Karakatsoulis, Georgios et al.

Part of Leukemia, p. 3444-3454, 2021

• DOI for COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
• Download full text (pdf) of COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib

Svanberg, Rebecka; Ostrowski, Sisse Rye; Nasserinejad, Kazem; Kersting, Sabina et al.

Part of Leukemia and Lymphoma, p. 3422-3431, 2020

• DOI for Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib

High prevalence and incidence of cardiovascular disease in chronic lymphocytic leukaemia: a nationwide population-based study

Larsson, Karin; Mattsson, Mattias; Ebrahim, Fereshte; Glimelius, Ingrid et al.

Part of British Journal of Haematology, 2020

• DOI for High prevalence and incidence of cardiovascular disease in chronic lymphocytic leukaemia: a nationwide population-based study

Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations

Levin, Mark-David; Kater, Arnon P.; Mattsson, Mattias; Kersting, Sabina et al.

Part of BMJ Open, 2020

• DOI for Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations
• Download full text (pdf) of Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations

Increasing prevalence of chronic lymphocytic leukemia with an estimated future rise: a nationwide population-based study

Mattsson, Mattias; Sandin, Fredrik; Kimby, Eva; Höglund, Martin et al.

Part of American Journal of Hematology, 2020

• DOI for Increasing prevalence of chronic lymphocytic leukemia with an estimated future rise: a nationwide population-based study

5-year Follow up After MSC-based Treatment of Severe Acute Respiratory Distress Syndrome

Simonson, Oscar; Ståhle, Elisabeth; Hansen, Tomas; Wedin, Johan O et al.

Part of American Journal of Respiratory and Critical Care Medicine, p. 1051-1055, 2020

• DOI for 5-year Follow up After MSC-based Treatment of Severe Acute Respiratory Distress Syndrome
• Download full text (pdf) of 5-year Follow up After MSC-based Treatment of Severe Acute Respiratory Distress Syndrome

Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification

Trizuljak, Jakub; Sperr, Wolfgang R.; Nekvindova, Lucie; Elberink, Hanneke O. et al.

Part of Allergy. European Journal of Allergy and Clinical Immunology, p. 1927-1938, 2020

• DOI for Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification

International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia

Condoluci, Adalgisa; di Bergamo, Lodovico Terzi; Langerbeins, Petra; Hoechstetter, Manuela A. et al.

Part of Blood, p. 1859-1869, 2020

• DOI for International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia

The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome

Brieghel, Christian; da Cunha-Bang, Caspar; Yde, Christina Westmose; Schmidt, Ane Yde et al.

Part of Clinical Cancer Research, p. 1507-1515, 2020

• DOI for The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome

Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry

Kluin-Nelemans, Hanneke C.; Reiter, Andreas; Illerhaus, Anja; van Anrooij, Bjorn et al.

Part of Leukemia, p. 1090-1101, 2020

• DOI for Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry

Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia

Baliakas, Panagiotis; Moysiadis, Theodoros; Hadzidimitriou, Anastasia; Xochelli, Aliki et al.

Part of Haematologica, p. 360-369, 2019

• DOI for Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia
• Download full text (pdf) of Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia

Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis

Grootens, Jennine; Ungerstedt, Johanna S.; Ekoff, Maria; Rönnberg, Elin et al.

Part of EBioMedicine, p. 150-158, 2019

• DOI for Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis
• Download full text (pdf) of Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis

Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort

Winqvist, Maria; Andersson, Per-Ola; Asklid, Anna; Karlsson, Karin et al.

Part of Haematologica, 2019

• DOI for Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort
• Download full text (pdf) of Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort

First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013

Sylvan, Sandra Eketorp; Asklid, Anna; Johansson, Hemming; Klintman, Jenny et al.

Part of Haematologica, p. 797-805, 2019

• DOI for First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013

No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy

Baliakas, Panagiotis; Mattsson, Mattias; Hadzidimitriou, Anastasia; Minga, Eva et al.

Part of Haematologica, 2018

• DOI for No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy

Serological reactivity to Anaplasma phagocytophilum in neoehrlichiosis patients

Wass, Linda; Grankvist, Anna; Mattsson, Mattias; Gustafsson, Helena et al.

Part of European Journal of Clinical Microbiology and Infectious Diseases, p. 1673-1678, 2018

• DOI for Serological reactivity to Anaplasma phagocytophilum in neoehrlichiosis patients
• Download full text (pdf) of Serological reactivity to Anaplasma phagocytophilum in neoehrlichiosis patients

Continuous Increasing Prevalence of Chronic Lymphocytic Leukemia (CLL) with an Estimated Future Rise-a Nationwide Population-Based Study from Sweden

Mattsson, Mattias; Sandin, Fredrik; Kimby, Eva; Höglund, Martin et al.

Part of Blood, 2018

• DOI for Continuous Increasing Prevalence of Chronic Lymphocytic Leukemia (CLL) with an Estimated Future Rise-a Nationwide Population-Based Study from Sweden

Spontaneous Clinical Regression In Chronic Lymphocytic Leukemia: Clinical And Biologic Features Of 9 Cases From The ERIC Registry

Del Giudice, I.; Visentin, A.; Trentin, L.; Flogegard, M. et al.

Part of Haematologica, p. 714-714, 2017

Spontaneous Clinical Regression In Chronic Lymphocytic Leukemia: Clinical And Biologic Features Of 9 Cases From The ERIC Registry

Del Giudice, I.; Visentin, A.; Trentin, L.; Flogegard, M. et al.

Part of Haematologica, p. 121-122, 2017

Is FCR the treatment of choice for IGHV mutated CLL without poor FISH cytogenetics?

Baliakas, Panagiotis; Moreno, Carol; Cuellar, Carolina; Scarfo, Lydia et al.

Part of Leukemia and Lymphoma, p. 170-171, 2017

• DOI for Is FCR the treatment of choice for IGHV mutated CLL without poor FISH cytogenetics?

Natural IgM antibodies in the immune defence against neoehrlichiosis

Wennerås, Christine; Goldblatt, David; Zancolli, Marta; Mattsson, Mattias et al.

Part of Infectious Diseases, p. 809-816, 2017

• DOI for Natural IgM antibodies in the immune defence against neoehrlichiosis

Prognostic impact of epigenetic classification in chronic lymphocytic leukemia: The case of subset #2

Bhoi, Sujata; Ljungström, Viktor; Baliakas, Panagiotis; Mattsson, Mattias et al.

Part of Epigenetics, p. 449-455, 2016

• DOI for Prognostic impact of epigenetic classification in chronic lymphocytic leukemia: The case of subset #2

No Improvement In Long-Term Overall Survival After The Introduction Of Chemo(Immuno)Therapy For Chronic Lymphocytic Leukemia Patients Belonging To Stereotyped Subset #2

Baliakas, Panagiotis; Mattsson, Mattias; Hadzidimitriou, A.; Minga, E. et al.

Part of Haematologica, p. 231-231, 2016

UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?

Bhoi, Sujata; Baliakas, Panagiotis; Cortese, Diego; Mattsson, Mattias et al.

Part of Haematologica, 2016

• DOI for UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.

Winqvist, Maria; Asklid, Anna; Andersson, P O; Karlsson, Karin et al.

Part of Haematologica, p. 1573-1580, 2016

• DOI for Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.

Ex Vivo Lymph Node Native Microenvironment Assay Shows Novel Antiproliferative Activity For Idelalisib And Ibrutinib On Cll Cells

Ballesteros, J.; Scarfo, L.; Mattsson, Mattias; Xochelli, A. et al.

Part of Haematologica, p. 426-426, 2016

Personalized Modeling of Disease Evolution in CLL: Does Statistical Significance Translate into Predictive Accuracy?

Chatzilari, Elisavet; Baliakas, Panagiotis; Xochelli, Aliki; Maronidis, Anastasios et al.

Part of Blood, 2015

Personalized Modeling of Disease Evolution in CLL: Does Statistical Significance Translate into Predictive Accuracy?

Chatzilari, Elisavet; Baliakas, Panagiotis; Xochelli, Aliki; Maronidis, Anastasios et al.

Part of Blood, 2015

REFINING PROGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH SOMATICALLY HYPERMUTATED B-CELL RECEPTORS: A NOVEL PROGNOSTIC INDEX ON BEHALF OF THE EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC)

Baliakas, Panagiotis; Hadzidimitriou, A.; Mattsson, Mattias; Xochelli, Aliki et al.

Part of Haematologica, p. 52-52, 2015

In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome

Simonson, Oscar E.; Mougiakakos, Dimitrios; Heldring, Nina; Bassi, Giulio et al.

Part of Stem Cells Translational Medicine, p. 1199-1213, 2015

• DOI for In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome

Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program

Hansson, Lotta; Winqvist, Maria; Asklid, Anna; Andersson, P-O et al.

Part of Blood, 2015

An Innovative High-Throughput Ex Vivo Drug Assay Incorporating the Native Microenvironment Reveals a Novel Mechanism of Action of Idelalisib in CLL

Ballesteros, Joan; Scarfo, Lydia; Mattsson, Mattias; Xochelli, Aliki et al.

Part of Blood, 2015

First report from the Swedish CLL-registry: a nationwide registry with high coverage

Kimby, Eva; Abrahamsson, Marie; Mattsson, Mattias

Part of Leukemia and Lymphoma, p. 42-42, 2015

Clonal evolution patterns in high-risk chronic lymphocytic leukemia treated with ibrutinib

Mattsson, Mattias; Ljungström, Viktor; Djureinovic, Tatjana; Mansouri, Larry et al.

The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives

Valent, Peter; Elberink, Joanna N. G. Oude; Gorska, Aleksandra; Lange, Magdalena et al.

Part of Journal of Allergy and Clinical Immunology, p. 81-87, 2019

• DOI for The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives

Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed?

Baliakas, Panagiotis; Mattsson, Mattias; Stamatopoulos, Kostas; Rosenquist Brandell, Richard

Part of Journal of Internal Medicine, p. 347-357, 2016

• DOI for Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed?

BTK-inhibitors: Focus on Ibrutinib and similar Agents

Mattsson, Mattias; Scarfo, Lydia

Part of Resistance of targeted therapies excluding antibodies for lymphomas, Springer, 2018

• DOI for BTK-inhibitors: Focus on Ibrutinib and similar Agents

Chronic lymphocytic leukemia: Studies from genetics to epidemiology with focus on the impact of different treatments

Mattsson, Mattias

2020

• Download full text (pdf) of Chronic lymphocytic leukemia: Studies from genetics to epidemiology with focus on the impact of different treatments

Isolated subclonal mutations are not a common feature in untreated chronic lymphocytic leukemia

Larsson, Karin; Young, Emma; Höglund, Martin; Mattsson, Mattias et al.

Population-based incidence, prevalence and survival of systemic AL amyloidosis in Sweden

Rosengren, Sara; Thelander, Ulrika; Mattsson, Mattias; Carlson, Kristina